Piramal Pharma Solutions (PPS), a CDMO (contract development and manufacturing organization), is investing $80 million in expanding its facility in Lexington, Kentucky. The site is dedicated to sterile compounding, liquid filling, and lyophilisation of injectable drugs and plays a vital role in Piramal’s ADCelerate program for antibody-drug conjugate (ADC) development.
The expansion will add 24,000 square feet to the current site, along with advanced equipment such as a new filling line, two large lyophilisers, a capping machine, and an external vial washer.
With these upgrades, the facility’s production capacity will increase from 104 batches per year to more than 240 by early 2027. The investment comes in response to the growing demand for sterile injectable drug products.
Nandini Piramal, Chairperson of Piramal Pharma Ltd., described the expansion as a strategic step for the company’s future growth. The aim is to establish the Lexington site as a major player in the expanding injectables market.
As reported by PharmaSource, Peter DeYoung, CEO of Global Pharma, emphasized the significance of the project, stating that the increased capacity and capabilities would further strengthen Piramal Pharma’s role as a comprehensive partner across all stages of the product life cycle.
